Why the study?
Vitamin D deficiency has been associated with susceptibility to infectious disease, prompting an evaluation of the association between vitamin D levels and COVID-19 outcomes.
Is Vitamin D deficiency associated with increased COVID-19 severity and mortality in patients with confirmed COVID-19?
Is Vitamin D deficiency associated with increased COVID-19 severity and mortality in patients with confirmed COVID-19?
Vitamin D deficiency is independently associated with increased COVID-19 mortality, an effect partly mediated by pro-thrombotic and myocardial injury markers, independent of visceral adiposity.
Evidence Level:** Level 5 -> Must use LEAVES OPEN framing. Cautious language.
INTRODUCTION: Coronavirus disease (COVID-19) is a global pandemic. Vitamin D deficiency has been associated with susceptibility to infectious disease. In this study, the association between COVID-19 outcomes and vitamin D levels in patients attending a COVID-19 reference center in Mexico City are examined. METHODS: Consecutive patients with confirmed COVID-19 were evaluated. All patients underwent clinical evaluation and follow-up, laboratory measurements and a thoracic computerized tomography, including the measurement of epicardial fat thickness. Low vitamin D was defined as levels <20 ng/ml (<50nmol/L) and deficient Vitamin D as a level ≤12 ng/ml (<30 nmol/L). RESULTS: = 0.006) but not with critical COVID-19, adjusted for age, sex, body-mass index and epicardial fat. Using model-based causal mediation analyses the increased risk of COVID-19 mortality conferred by low vitamin D levels was partly mediated by its effect on D-dimer and cardiac ultrasensitive troponins. Notably, increased risk of COVID-19 mortality conferred by low vitamin D levels was independent of BMI and epicardial fat. CONCLUSION: Vitamin D deficiency (≤12 ng/ml or <30 nmol/L), is independently associated with COVID-19 mortality after adjustment for visceral fat (epicardial fat thickness). Low vitamin D may contribute to a pro-inflammatory and pro-thrombotic state, increasing the risk for adverse COVID-19 outcomes.
No takes yet. Share an insight, caveat, or question.
Vanegas-Cedillo et al. (2022) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: